Sugi Predict

Sugi Predict / Targets / RHOA

RHOA

Transforming protein RhoA · P61586 · RHOA on Sugi Atlas →

13,580 patent compounds predicted against RHOA, 7,351 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1534280 SCHEMBL1534280 0.73 19/20
SCHEMBL1534248 SCHEMBL1534248 0.64 19/20
SCHEMBL1534209 SCHEMBL1534209 1.00 18/20
SCHEMBL1534454 SCHEMBL1534454 1.00 17/20
SCHEMBL1534160 SCHEMBL1534160 0.67 17/20
SCHEMBL1534302 SCHEMBL1534302 0.54 16/20
SCHEMBL419296 SCHEMBL419296 0.61 15/20
SCHEMBL1534232 SCHEMBL1534232 0.54 14/20
SCHEMBL1534236 SCHEMBL1534236 1.00 13/20
SCHEMBL1534247 SCHEMBL1534247 1.00 13/20
SCHEMBL418890 SCHEMBL418890 0.67 13/20
SCHEMBL1534304 SCHEMBL1534304 0.64 13/20
SCHEMBL416972 SCHEMBL416972 0.56 13/20
SCHEMBL1534265 SCHEMBL1534265 1.00 12/20
SCHEMBL1534393 SCHEMBL1534393 1.00 12/20
SCHEMBL417952 SCHEMBL417952 0.62 12/20
SCHEMBL419591 SCHEMBL419591 0.57 11/20
SCHEMBL416973 SCHEMBL416973 0.57 11/20
SCHEMBL1553823 SCHEMBL1553823 0.55 11/20
SCHEMBL1534267 SCHEMBL1534267 1.00 10/20

Clinical trials — most relevant to RHOA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension PHASE4RECRUITING
Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD PHASE4UNKNOWN
Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients PHASE2/PHASE3UNKNOWN
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma PHASE3COMPLETED
Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation PHASE2ENROLLING_BY_INVITATION
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
SCARFREE-001: Verteporfin for Scar Prevention PHASE2NOT_YET_RECRUITING
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula PHASE2COMPLETED
Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis PHASE2COMPLETED
Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
The Continuous Positive Airway Pressure Effect on Rho-associated Coiled-coil Containing Kinases Activity. nanUNKNOWN
Screening and Identification of Biomarkers for High Myopia by a Rapid Method nanUNKNOWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
Efficacy of Biological Technique in Upper Canine Retraction and Levels of Discomfort nanCOMPLETED
Longitudinal Observational Study of Severe Asthma nanCOMPLETED
Circulating Activin-A and FSTL3 in Precapillary Pulmonary Hypertension nanACTIVE_NOT_RECRUITING
The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure nanCOMPLETED
The Activation of Hippo Pathway in Nasal Polyps nanUNKNOWN
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases nanNOT_YET_RECRUITING
Immune Cell Response to Stimuli nanRECRUITING
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN
Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis nanCOMPLETED
Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis nanUNKNOWN
Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System nanCOMPLETED
Airway Smooth Muscle and Asthma Severity nanCOMPLETED
Statin Therapy and COVID-19 Infection nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RHOA binder may also engage these)

ProteinNameSimilarity
P61589 — 1.000 P61589 →
P24406 — 1.000 P24406 →
P61585 — 1.000 P61585 →
Q7T2E8 — 1.000 Q7T2E8 →
Q6NUX8 — 1.000 Q6NUX8 →
P01122 — 1.000 P01122 →
Q9QUI0 — 1.000 Q9QUI0 →
Q5REY6 — 1.000 Q5REY6 →
Q1RMJ6 — 0.999 Q1RMJ6 →
Q9PSX7 — 0.999 Q9PSX7 →
P48148 — 0.996 P48148 →
Q22038 — 0.994 Q22038 →
Q9C3Y4 — 0.993 Q9C3Y4 →
Q6DHE8 — 0.992 Q6DHE8 →
RHOC Rho-related GTP-binding protein RhoC 0.992 landscape →
Q62159 — 0.992 Q62159 →
Q5RCK9 — 0.992 Q5RCK9 →
Q6DHM9 — 0.991 Q6DHM9 →
P62747 — 0.990 P62747 →
Q3ZBW5 — 0.988 Q3ZBW5 →
P62746 — 0.984 P62746 →
RAC1 Ras-related C3 botulinum toxin substrate 1 0.983 landscape →
P62999 — 0.983 P62999 →
P62745 — 0.983 P62745 →
P22122 — 0.982 P22122 →
P62998 — 0.981 P62998 →
Q03206 — 0.980 Q03206 →
P40792 — 0.979 P40792 →
RAC3 Ras-related C3 botulinum toxin substrate 3 0.978 landscape →
P60764 — 0.978 P60764 →